Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 2
2008 2
2009 1
2012 1
2013 3
2014 4
2015 4
2016 2
2017 3
2018 1
2019 1
2020 4
2021 1
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma.
Haas L, Elewaut A, Gerard CL, Umkehrer C, Leiendecker L, Pedersen M, Krecioch I, Hoffmann D, Novatchkova M, Kuttke M, Neumann T, da Silva IP, Witthock H, Cuendet MA, Carotta S, Harrington KJ, Zuber J, Scolyer RA, Long GV, Wilmott JS, Michielin O, Vanharanta S, Wiesner T, Obenauf AC. Haas L, et al. Among authors: pedersen m. Nat Cancer. 2021 Jul;2(7):693-708. doi: 10.1038/s43018-021-00221-9. Epub 2021 Jul 15. Nat Cancer. 2021. PMID: 35121945 Free PMC article.
Isolation and Analysis of Tumor-Infiltrating Treg.
Bergerhoff K, Pedersen M. Bergerhoff K, et al. Among authors: pedersen m. Methods Mol Biol. 2023;2559:51-63. doi: 10.1007/978-1-0716-2647-4_5. Methods Mol Biol. 2023. PMID: 36180626
Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade.
Patin EC, Dillon MT, Nenclares P, Grove L, Soliman H, Leslie I, Northcote D, Bozhanova G, Crespo-Rodriguez E, Baldock H, Whittock H, Baker G, Kyula J, Guevara J, Melcher AA, Harper J, Ghadially H, Smith S, Pedersen M, McLaughlin M, Harrington KJ. Patin EC, et al. Among authors: pedersen m. J Immunother Cancer. 2022 Mar;10(3):e004306. doi: 10.1136/jitc-2021-004306. J Immunother Cancer. 2022. PMID: 35314434 Free PMC article.
Combination therapy with oncolytic viruses and immune checkpoint inhibitors.
Chiu M, Armstrong EJL, Jennings V, Foo S, Crespo-Rodriguez E, Bozhanova G, Patin EC, McLaughlin M, Mansfield D, Baker G, Grove L, Pedersen M, Kyula J, Roulstone V, Wilkins A, McDonald F, Harrington K, Melcher A. Chiu M, et al. Among authors: pedersen m. Expert Opin Biol Ther. 2020 Jun;20(6):635-652. doi: 10.1080/14712598.2020.1729351. Epub 2020 Feb 23. Expert Opin Biol Ther. 2020. PMID: 32067509 Review.
ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment.
Dillon MT, Bergerhoff KF, Pedersen M, Whittock H, Crespo-Rodriguez E, Patin EC, Pearson A, Smith HG, Paget JTE, Patel RR, Foo S, Bozhanova G, Ragulan C, Fontana E, Desai K, Wilkins AC, Sadanandam A, Melcher A, McLaughlin M, Harrington KJ. Dillon MT, et al. Among authors: pedersen m. Clin Cancer Res. 2019 Jun 1;25(11):3392-3403. doi: 10.1158/1078-0432.CCR-18-1821. Epub 2019 Feb 15. Clin Cancer Res. 2019. PMID: 30770349 Free PMC article.
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma.
Bozhanova G, Hassan J, Appleton L, Jennings V, Foo S, McLaughlin M, Chan Wah Hak CM, Patin EC, Crespo-Rodriguez E, Baker G, Armstrong E, Chiu M, Pandha H, Samson A, Roulstone V, Kyula J, Vile R, Errington-Mais F, Pedersen M, Harrington K, Ono M, Melcher A. Bozhanova G, et al. Among authors: pedersen m. J Immunother Cancer. 2022 Mar;10(3):e004410. doi: 10.1136/jitc-2021-004410. J Immunother Cancer. 2022. PMID: 35338089 Free PMC article.
32 results